NEW YORK, Sept. 8 (UPI) -- Bristol-Myers Squibb and Sanofi said Friday the U.S. Food and Drug Administration has OK'd Plavix to prevent fatal heat attack.
The companies said FDA approved expanded use of the anti-clotting drug to reduce the risk of death from any cause and the risk of a combined endpoint of recurrent heart attack, stroke or death in patients with acute STEMI.
STEMI is the most severe form of heart attack and is marked by complete blockage of an artery, the companies said.
Patients who have survived a STEMI incident are at higher risk of another heart attack, stroke or death. More than 300,000 people in the United States experience a STEMI heart attack each year, the companies said.